Back
Sanofi, GSK Initiate Second Phase trial of Protein-based COVID-19 Vaccine
Sep 28, 2020
Raheem Akingbolu Pharmaceutical giants, Sanofi and GlaxoSmithKline have jointly announced the commencement of phase II clinical trial for an adjuvant COVID-19 vaccine.
The vaccine candidate, jointly developed by the two global companies, uses the same recombinant protein-based technology as one of Sanofi’s seasonal influenza vaccines with GSK’s established pandemic adjuvant technology.
In a recent statement, President of GSK Vaccines, Roger Connor, disclosed that the randomised, double-blind and placebo-controlled clinical trial was designed to evaluate the safety, tolerability and immune response of the COVID-19 vaccine candidate. “Moving this vaccine candidate into clinical development is an important moment in the progress towards addressing the global pandemic we are all facing.
“This builds on the confidence shown by governments already in the potential of this protein-based adjuvant vaccine candidate, which utilises established technology from both companies.
“We now look forward to the data from the study, and if positive, beginning a phase III trial by the end of the year,” he said. A total of 440 healthy adults are being enrolled in the trial across 11 investigational sites in the United States.
Connor disclosed that both companies anticipate the first results in early December 2020, to support the initiation of a Phase III trial in December 2020.
0Shares
0Comments
0Favorites
0Likes
Say something to impress...
Loading...
Comments
Hot

No content at this moment.

Relevant people
Up Day
22085 Followers
others
News up to date
Related